Ascletis Pharma announced positive results from its Phase Ia single ascending dose (SAD) study of ASC30, a novel small-molecule oral GLP-1 receptor agonist (RA) for obesity treatment. The study ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Glucagon-like peptide-1 receptor agonist medications for weight loss are significantly transforming the field of facial plastic surgery.

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

Image: Adobe Stock GLP-1 receptor agonists may possess certain neurotrophic properties that delay disease progression, Vijiaratnam and colleagues wrote. Small, randomized trials have suggested ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

"GLP-1 agonists ... weight using GLP-1 agonist drugs but are planning to discontinue the treatment. RDX-002, Response Pharmaceuticals' lead candidate, is an investigational first-in-class, potent, ...